Zanidatamab
Zymeworks,Jazz
['bcsm', 'zanidatamab', 'zanida']
continuing her2 story in biliary tract cancers, bispecific ab zanidatamab (herizon-btc-01): orr: 41.3%, 1 cr median dor: 12.9 months median pfs: 5.5 months, os not mature
most common aes: diarrhea, infusion reactions, rare cardiac events
#asco23 #hpbcsm #cancerresearch 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own